355 related articles for article (PubMed ID: 34258739)
1. Moving Fast Toward Hepatitis B Virus Elimination.
Bassit L; Ono SK; Schinazi RF
Adv Exp Med Biol; 2021; 1322():115-138. PubMed ID: 34258739
[TBL] [Abstract][Full Text] [Related]
2. The premise of capsid assembly modulators towards eliminating HBV persistence.
Bassit L; Amblard F; Patel D; Biteau N; Chen Z; Kasthuri M; Zhou S; Schinazi RF
Expert Opin Drug Discov; 2023; 18(9):1031-1041. PubMed ID: 37477111
[TBL] [Abstract][Full Text] [Related]
3. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.
Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556
[TBL] [Abstract][Full Text] [Related]
4. Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies.
Singh A; Kumar J; Kumar V
Curr Top Med Chem; 2023; 23(18):1727-1752. PubMed ID: 37069708
[TBL] [Abstract][Full Text] [Related]
5. Can we cure hepatitis B virus with novel direct-acting antivirals?
Martinez MG; Villeret F; Testoni B; Zoulim F
Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597
[TBL] [Abstract][Full Text] [Related]
6. Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.
Kim SW; Yoon JS; Lee M; Cho Y
Clin Mol Hepatol; 2022 Jan; 28(1):17-30. PubMed ID: 34281294
[TBL] [Abstract][Full Text] [Related]
7. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
Revill P; Locarnini S
Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic strategies for chronic hepatitis B.
Phillips S; Jagatia R; Chokshi S
Virulence; 2022 Dec; 13(1):1111-1132. PubMed ID: 35763282
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731.
Huang Q; Cai D; Yan R; Li L; Zong Y; Guo L; Mercier A; Zhou Y; Tang A; Henne K; Colonno R
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868329
[TBL] [Abstract][Full Text] [Related]
10. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections.
Martinez MG; Boyd A; Combe E; Testoni B; Zoulim F
J Hepatol; 2021 Sep; 75(3):706-717. PubMed ID: 34051332
[TBL] [Abstract][Full Text] [Related]
11. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B.
Goh ZY; Ren EC; Ko HL
World J Gastroenterol; 2021 Apr; 27(14):1369-1391. PubMed ID: 33911462
[TBL] [Abstract][Full Text] [Related]
12. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
[TBL] [Abstract][Full Text] [Related]
13. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
14. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
[TBL] [Abstract][Full Text] [Related]
15. [A short half-life of cccDNA offer or ignite hope for hepatitis B cure under nucleos(t)ide analogues treatment].
Gao L; Mao TH; Peng SW; Wang J; Chen XM; Lu FM
Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):99-102. PubMed ID: 35152678
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus: new therapeutic perspectives.
Lin CL; Yang HC; Kao JH
Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel cccDNA Reducers toward the Cure of Hepatitis B Virus Infection.
Chen D; Tan X; Chen W; Liu Y; Li C; Wu J; Zheng J; Shen HC; Zhang M; Wu W; Wang L; Xiong J; Dai J; Sun K; Zhang JD; Xiang K; Li B; Ni X; Zhu Q; Gao L; Wang L; Feng S
J Med Chem; 2022 Aug; 65(16):10938-10955. PubMed ID: 35973101
[TBL] [Abstract][Full Text] [Related]
18. The progress of molecules and strategies for the treatment of HBV infection.
Pan Y; Xia H; He Y; Zeng S; Shen Z; Huang W
Front Cell Infect Microbiol; 2023; 13():1128807. PubMed ID: 37009498
[TBL] [Abstract][Full Text] [Related]
19. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
[TBL] [Abstract][Full Text] [Related]
20. The current status and future directions of hepatitis B antiviral drug discovery.
Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
